Table 2 Results for binary logistic regression analysis using comorbidities and exposure to drugs in IBS
| Â | IBS patients N = 287 | Controls N = 287 | OR [95% CI] uncorrected for comorbidities | OR [95% CI] corrected for comorbidities | OR [95% CI] excluding patients with psychiatric comorbidity | OR [95%] excluding patients with RA or arthritis | OR [95% CI] excluding patients with GERD/FD |
|---|---|---|---|---|---|---|---|
FD or GERD | 25.2% | 9.8% | NA | 2.0 [1.1-3.5] | 2.8 [1.5-5.2] | 2.1 [1.8-3.8] | NA |
Psychiatric comorbidity | 40.4% | 3.5% | NA | 16.6 [7.9-34.8] | NA | 17.0 [8.0-36.2] | 33.3 [11.6-95.5] |
Fibromyalgia | 4.4% | 0% | NA | NA | NA | NA | NA |
Rheumatoid arthritis | 6.1% | 0% | NA | NA | NA | NA | NA |
PPIs | 21.2% | 5.2% | 2.2 [1.1-5.0] | 2.1 [1.1-4.1] | 3.0 [1.3-7.0] | 3.1 [1.5-6.2] | 2.1 [0.8-5.4] |
NSAIDs | 20.55% | 3.8% | 3.8 [1.7-8.6] | 5.2 [2.5-11.0] | 4.1 [1.7-9.6] | 5.7 [2.65-12.2] | 5.5 [2.3-13.3] |
SSRIs | 10.84% | 2.1% | 3.7 [1.3-10.9] | 0.9 [0.3-2.7] | 6.3 [0.7-56.8] | 0.75 [0.25-2.3] | 2.8 [0.5-14.7] |
Diuretics | 5.2% | 2.8% | 1.0 [0.3-3.6] | 1.1 [0.3-3.4] | 2.4 [0.7-7.9] | 1.4 [0.5-3.7] | 2.6 [0.8-9.6] |
ACE-I | 2.8% | 1.4% | 1.2 [0.2-4.0] | 1.4 [0.3-6.0] | 0.9 [0.2-4.4] | 1.3 [0.3-5.2] | 0.8 [0.1-5.0] |